Mitsubishi UFJ Asset Management Co. Ltd. Takes $78.51 Million Position in IQVIA Holdings Inc. $IQV

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 406,318 shares of the medical research company’s stock, valued at approximately $78,509,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.25% of IQVIA at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Brighton Jones LLC boosted its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its stake in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA in the second quarter worth $514,000. First Trust Advisors LP boosted its position in IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC grew its stake in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 0.4%

NYSE IQV opened at $240.25 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $251.36. The stock has a market capitalization of $39.54 billion, a PE ratio of 29.81, a PEG ratio of 2.01 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The business’s 50-day moving average is $208.88 and its 200 day moving average is $186.72.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the prior year, the company posted $2.81 EPS. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has approved a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Mizuho raised their price target on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. lifted their price target on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. William Blair upgraded IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Robert W. Baird raised their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 12,913 shares of company stock worth $3,098,793. Insiders own 1.70% of the company’s stock.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.